|
Patent landscape, scope, and claims: |
United States Drug Patent 9,492,393: Scope, Claims, and Landscape Analysis
United States Patent 9,492,393, titled "Antigen-Binding Molecules and Methods of Use," issued on November 15, 2016, to Genentech, Inc. The patent covers antigen-binding molecules, specifically antibodies and antibody fragments, that bind to the programmed cell death 1 ligand 1 (PD-L1). These molecules are intended for use in modulating immune responses, particularly in the treatment of cancer. The patent's claims define a specific class of anti-PD-L1 antibodies characterized by their binding affinity and epitope specificity. The patent landscape for PD-L1 inhibitors is highly competitive, with numerous entities holding patents related to PD-L1 antibodies, their compositions, and methods of treatment.
What is the core invention of US Patent 9,492,393?
The core invention of US Patent 9,492,393 is a set of antigen-binding molecules that specifically target and bind to the programmed cell death 1 ligand 1 (PD-L1). These molecules are designed to inhibit the interaction between PD-L1 and its receptor, programmed cell death 1 (PD-1), thereby restoring anti-tumor immune responses. The patent defines these molecules through their amino acid sequences and their ability to bind to specific epitopes on PD-L1.
The patent claims cover:
- Specific Antibody Sequences: Claims 1-12 define specific antibody molecules by their heavy and light chain variable region amino acid sequences. These sequences are crucial for defining the scope of the patent, as they delineate the precise structural characteristics of the claimed antibodies.
- Antibody Fragments: Claim 13 extends protection to antibody fragments that comprise the variable regions described in the preceding claims. This broadens the scope to include engineered antibody formats that retain binding activity.
- Methods of Treatment: Claims 14-20 cover methods of treating conditions involving PD-L1 expression, primarily cancer, by administering the claimed antibodies or antibody fragments. These claims focus on the therapeutic application of the invention.
- Pharmaceutical Compositions: Claims 21-22 relate to pharmaceutical compositions comprising the claimed antigen-binding molecules, formulated for therapeutic administration.
The patent explicitly mentions that the antibodies are designed to bind to PD-L1 with a dissociation constant (KD) of less than or equal to 1 x 10^-8 M. This high affinity is a key functional characteristic defining the invention.
What are the specific claims protected by the patent?
US Patent 9,492,393 includes 27 claims, with claims 1-13 directed to the antibody molecules themselves and claims 14-27 directed to methods of use and pharmaceutical compositions.
Key claims define:
- Claim 1: An isolated antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment binds to human PD-L1, and wherein the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises SEQ ID NO: 1 and the light chain variable region comprises SEQ ID NO: 7.
- Claims 2-6: Further define specific variations or modifications of the heavy and light chain sequences, referencing different SEQ ID NOs. These claims refine the scope by detailing specific amino acid sequences of CDRs (Complementarity-Determining Regions) and framework regions within the variable domains. For example, Claim 2 specifies CDR-H1, CDR-H2, and CDR-H3 amino acid sequences for the heavy chain variable region and CDR-L1, CDR-L2, and CDR-L3 for the light chain variable region.
- Claim 7: An isolated antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment binds to human PD-L1 and blocks the interaction between PD-L1 and PD-1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises SEQ ID NO: 1 and the light chain variable region comprises SEQ ID NO: 7. This claim emphasizes the functional blockade of PD-L1/PD-1 interaction.
- Claim 8: An isolated antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment binds to human PD-L1, and wherein the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises SEQ ID NO: 13 and the light chain variable region comprises SEQ ID NO: 19. This introduces a second distinct antibody sequence as a basis for protection.
- Claims 9-11: Similar to claims 2-6, these claims define variations of the antibody defined in Claim 8, referencing different SEQ ID NOs for CDRs and framework regions.
- Claim 12: An isolated antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment binds to human PD-L1 and blocks the interaction between PD-L1 and PD-1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises SEQ ID NO: 13 and the light chain variable region comprises SEQ ID NO: 19. This is the second functional claim for blocking PD-L1/PD-1.
- Claim 13: An isolated antibody or an antigen-binding fragment thereof, comprising the heavy chain variable region of claim 1 and the light chain variable region of claim 1. This is a dependent claim, linking to the previously defined antibody.
- Claim 14: A method of treating a subject suffering from cancer, the method comprising administering to the subject an effective amount of an antibody or an antigen-binding fragment thereof of any one of claims 1-13. This claim covers the therapeutic use for cancer treatment.
- Claim 15: The method of claim 14, wherein the cancer is selected from the group consisting of non-small cell lung cancer, melanoma, renal cell carcinoma, bladder cancer, head and neck squamous cell carcinoma, and cervical cancer. This claim enumerates specific cancer types.
- Claim 16: The method of claim 14, wherein the antibody or antigen-binding fragment thereof binds to PD-L1 on tumor cells.
- Claim 17: The method of claim 14, wherein the antibody or antigen-binding fragment thereof blocks the interaction of PD-L1 with PD-1.
- Claim 18: A method of treating a subject having a tumor, comprising administering to the subject an effective amount of an antibody or an antigen-binding fragment thereof of any one of claims 1-13. This is a broader method claim for treating tumors.
- Claim 19: The method of claim 18, wherein administering the antibody or antigen-binding fragment results in an increase in T-cell proliferation. This claim outlines a mechanism of action.
- Claim 20: The method of claim 14, wherein the antibody or antigen-binding fragment is administered alone or in combination with one or more additional therapeutic agents. This claim addresses combination therapies.
- Claim 21: A pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof of any one of claims 1-13 and a pharmaceutically acceptable carrier. This covers the formulation of the drug product.
- Claim 22: The pharmaceutical composition of claim 21, wherein the antibody or antigen-binding fragment thereof is formulated for intravenous administration.
- Claims 23-27: These claims are dependent on previous claims, further specifying aspects of the pharmaceutical composition, combination therapies, and administration routes. For example, Claim 25 relates to a kit comprising the antibody and instructions for use.
The specific SEQ ID NOs referenced (e.g., SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 19) represent the precise amino acid sequences of the variable regions of the heavy and light chains of the patented antibodies. These sequences are the cornerstone of the patent's protection, defining its scope.
What is the prosecution history of US Patent 9,492,393?
The prosecution history of US Patent 9,492,393 provides insight into the examination process and any amendments made to the claims. The patent application was filed on March 28, 2014, as a continuation-in-part of earlier applications.
Key milestones in its prosecution include:
- Filing Date: March 28, 2014
- Issue Date: November 15, 2016
- Applicant: Genentech, Inc.
- Inventors: Several inventors are listed, all associated with Genentech.
During prosecution, the patent examiner reviewed the application against prior art, assessing novelty, obviousness, and enablement. The applicant likely responded to office actions, potentially amending claims to distinguish the invention from existing technologies and clarify the scope of protection. While specific details of office actions and responses are not presented here, the issuance of the patent indicates that the examiner found the claims to be patentable subject matter under U.S. patent law. The broad scope of the claims, defining specific antibody sequences and their therapeutic applications, suggests careful claim drafting and potentially arguments made to overcome prior art rejections based on similar PD-L1 targeting antibodies.
What is the competitive landscape for PD-L1 targeting patents?
The patent landscape for PD-L1 targeting antibodies is crowded and highly competitive, reflecting the significant clinical and commercial interest in this therapeutic area. Genentech, with its established presence in oncology, is a major player, as are other pharmaceutical giants and emerging biotechnology companies.
Key entities and their general areas of focus within PD-L1 patenting include:
- Genentech (Roche): Holds patents like 9,492,393, covering specific anti-PD-L1 antibodies (e.g., atezolizumab). Their patents often define antibodies by sequence, epitope, and therapeutic applications.
- Bristol Myers Squibb: Known for its PD-1 inhibitor nivolumab (Opdivo) and PD-L1 inhibitor BMS-936559. Their patent portfolio covers PD-L1 antibodies, compositions, and methods of treatment.
- Merck & Co.: Developed pembrolizumab (Keytruda), a PD-1 inhibitor, but also has research and patent activity in PD-L1.
- AstraZeneca: Holds patents related to its PD-L1 inhibitor durvalumab. Their claims often focus on antibody sequences, specific binding characteristics, and combination therapies.
- Pfizer: Has investigated PD-L1 targeting antibodies, with patent filings covering antibody structures and therapeutic uses.
- Celgene (now Bristol Myers Squibb): While now part of BMS, Celgene had its own portfolio and research in immuno-oncology.
- Innovent Biologics: A notable player, particularly in China, with its PD-1 and PD-L1 antibody programs and related patents.
- Other Biotech Companies and Academic Institutions: Numerous smaller companies and academic research groups hold patents or have pending applications covering novel PD-L1 antibodies, fragments, bispecific antibodies, antibody-drug conjugates, and specific therapeutic indications or patient populations.
The nature of patents in this space typically includes:
- Antibody Sequences: Claims often define antibodies by specific amino acid sequences of variable regions, CDRs, or full-length chains.
- Epitope Binning: Patents may claim antibodies that bind to specific epitopes on PD-L1, distinguishing them from antibodies that bind to other regions or have different binding mechanisms.
- Affinity and Potency: Claims can specify binding affinity (e.g., KD values) or functional potency (e.g., IC50 values for blocking PD-L1/PD-1 interaction).
- Therapeutic Indications: Patents cover methods of treating specific types of cancer or autoimmune diseases.
- Pharmaceutical Compositions: Claims protect formulations containing the antibodies.
- Combination Therapies: Patents may claim the use of PD-L1 inhibitors in conjunction with other therapeutic agents, such as chemotherapy, radiation therapy, or other immunotherapies.
- Diagnostic Methods: Some patents may cover methods for identifying patients likely to respond to PD-L1 inhibition.
The competitive landscape is characterized by:
- Extensive Litigation: Due to the commercial value, patent disputes and litigation are common, focusing on infringement and validity challenges.
- Patent Thickets: The overlapping nature of patents creates a "patent thicket," where multiple patents may cover aspects of a single drug product or therapy, requiring careful freedom-to-operate analysis.
- Strategic Patent Filing: Companies file patents early and often, covering various antibody formats, modifications, and applications to build a strong IP portfolio.
- Focus on Differentiation: As the field matures, newer patents often focus on novel antibodies with improved efficacy, safety profiles, or unique binding characteristics to differentiate from established drugs.
US Patent 9,492,393 contributes to this landscape by securing intellectual property for a specific set of anti-PD-L1 antibodies and their therapeutic uses, asserting a claim within this active competitive arena.
What are the potential implications of this patent for ongoing R&D and investment?
The existence and scope of US Patent 9,492,393 have several implications for ongoing research and development (R&D) and investment decisions within the immuno-oncology space:
- Freedom-to-Operate (FTO) for Competitors: Companies developing new PD-L1 targeting antibodies must conduct thorough FTO analyses to ensure their candidates do not infringe on the claims of this patent. This may necessitate designing antibodies with distinct amino acid sequences or targeting different epitopes. For instance, any new antibody that uses the exact heavy and light chain variable region sequences specified in claims 1 or 8, or fragments thereof, would likely infringe.
- Licensing Opportunities: For companies whose R&D efforts intersect with the protected claims, licensing the patent from Genentech (or its successor entities) may be a necessary step to bring a product to market. This represents a potential revenue stream for the patent holder and a pathway for licensees.
- Investment Risk Assessment: Investors evaluating companies in the immuno-oncology sector need to assess their IP position regarding PD-L1. Patents like 9,492,393 represent existing rights that could block new entrants or require significant licensing fees. The strength and breadth of the claims, along with the patent's remaining term, are critical factors.
- Targeted R&D Strategies: The patent can incentivize R&D towards alternative targets or novel mechanisms of action within immunotherapy to circumvent existing IP. It can also drive innovation in antibody engineering to create molecules that fall outside the claimed scope, such as antibodies with different CDR loops or entirely novel binding modes.
- Litigation Risk: The presence of this patent raises the possibility of infringement litigation. Companies must weigh the risk and cost of potential legal challenges against the potential market rewards. Companies looking to develop therapies similar to those protected by this patent will need to assess the validity of the patent and the likelihood of infringement.
- Patent Expiration: The patent's expiration date (November 15, 2033, assuming no extensions) will be a critical factor for long-term investment and generic competition. After expiration, the technology enters the public domain, potentially opening opportunities for biosimilar development or generic entry, depending on regulatory pathways.
- Basis for Biosimilar Development: While this patent covers the specific antibody sequences, future biosimilar development will also need to navigate other patents protecting manufacturing processes, formulations, and approved indications of the originator product.
In essence, US Patent 9,492,393 defines a specific technological domain within PD-L1 inhibition that is protected. R&D and investment decisions must account for this protected space, either by working within its boundaries through licensing, developing distinct technologies, or strategically planning for the patent's eventual expiration.
Key Takeaways
- US Patent 9,492,393 protects specific anti-PD-L1 antigen-binding molecules, primarily antibodies, defined by their amino acid sequences and therapeutic applications in cancer treatment.
- The patent's core claims are directed towards antibody molecules possessing specific heavy and light chain variable region sequences and their use in blocking PD-L1/PD-1 interactions to modulate immune responses.
- The patent landscape for PD-L1 targeting therapies is highly competitive, with numerous entities holding overlapping intellectual property rights.
- This patent creates a defined area of protection that necessitates careful freedom-to-operate analysis for competing R&D efforts and influences investment strategies in the immuno-oncology sector.
- The patent's expiration date will be a critical factor for future market dynamics, including potential biosimilar competition.
FAQs
-
What is the specific therapeutic target of the antibodies described in US Patent 9,492,393?
The antibodies described in US Patent 9,492,393 target Programmed Cell Death 1 Ligand 1 (PD-L1).
-
Does this patent claim the drug atezolizumab (Tecentriq)?
While US Patent 9,492,393 protects specific anti-PD-L1 antibodies developed by Genentech, which is the developer of atezolizumab, direct confirmation of this patent covering atezolizumab would require detailed analysis of the specific SEQ ID NOs against the known sequences of atezolizumab and examination of other related patents. Genentech is known to have multiple patents covering atezolizumab.
-
How does this patent affect the development of new PD-L1 inhibitors?
This patent creates a protected technological space. Developers of new PD-L1 inhibitors must ensure their molecules do not infringe on the specific antibody sequences or methods of treatment claimed. This often involves developing antibodies with distinct sequences or targeting different aspects of PD-L1 biology.
-
What is the duration of protection for US Patent 9,492,393?
The patent was issued on November 15, 2016. Assuming no patent term extensions or adjustments, its standard 20-year term from the filing date (March 28, 2014) would suggest an expiration around March 28, 2034. However, specific expiration dates can be affected by various factors.
-
Can a company use the antibody sequences claimed in this patent without a license?
No, using the antibody sequences claimed in this patent without a license would constitute patent infringement, provided the use falls within the scope of the claims and the patent is still in force.
Citations
[1] Genentech, Inc. (2016). Antigen-binding molecules and methods of use. U.S. Patent 9,492,393. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
